Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.
The Burden of Sickle Cell Disease for Patients and Their Families
The Burden of Sickle Cell Disease for Patients and Their Families
Preventative Management of Sickle Cell Disease Complications
Preventative Management of Sickle Cell Disease Complications
A Quick Look at Standard Treatments for Sickle Cell Disease
A Quick Look at Standard Treatments for Sickle Cell Disease
Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan
Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan
Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
Implementing the Sickle Cell Treatment Regimen
Implementing the Sickle Cell Treatment Regimen
Why Do We Need New Therapies for Sickle Cell Disease?
Why Do We Need New Therapies for Sickle Cell Disease?
The HPV Vaccine Announcement for Children and Adolescents: HPV Cancer Prevention Starts with You
The HPV Vaccine Announcement for Children and Adolescents: HPV Cancer Prevention Starts with You
Keeping Pace in Hematologic Malignancies: 2023
Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Keeping Pace in Hematologic Malignancies: 2023
Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer
In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer